- Home
- VRCA vs ANVS Comparison
VRCA vs ANVS Comparison
Compare VRCA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | ANVS |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 111.3M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VRCA | ANVS |
|---|---|---|
| Price | $6.17 | $2.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $17.00 | $13.50 |
| AVG Volume (30 Days) | 122.3K | ★ 306.0K |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | N/A |
| Revenue This Year | $372.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.39 | $1.11 |
| 52 Week High | $9.82 | $5.50 |
Technical Indicators
Market Signals| Indicator | VRCA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 56.66 |
| Support Level | $5.22 | $2.29 |
| Resistance Level | $6.44 | $2.98 |
| Average True Range (ATR) | 0.46 | 0.20 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 69.87 | 69.44 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.